Holen Sie sich die Stockscreener-App
86.95
1.25%
1.07
Handel nachbörslich:
85.43
-1.52
-1.75%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$85.88
Offen:
$86.19
24-Stunden-Volumen:
3.78M
Relative Volume:
0.75
Marktkapitalisierung:
$50.07B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
47.24
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-1.84%
1M Leistung:
+1.36%
6M Leistung:
+0.83%
1J Leistung:
+15.44%
1-Tages-Spanne:
$85.46
$87.22
1-Wochen-Bereich:
$85.31
$89.14
52-Wochen-Spanne:
$72.30
$89.60
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
86.95 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
90.53 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
310.00 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.63 | 101.56B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.60 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences clears fresh Medicare hurdle, shares consolidate after 52-week high - Ad-hoc-news.de
SAPIEN 3 Ultra from Edwards Lifesciences Corp.lower-profile TAVI and refined delivery - AD HOC NEWS
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences Stocklong-term heart valve strategy in focus - AD HOC NEWS
Why Edwards Lifesciences’ Sapien 3 Ultra Resilia aims for quieter TAVI procedures - AD HOC NEWS
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
Edwards Lifesciences CEO Zovighian sells $45,982 of stock By Investing.com - Investing.com India
Edwards Lifesciences CEO Zovighian sells $45,982 of stock - Investing.com
Edwards Lifesciences Corp (EW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Edwards Lifesciences Corp (EW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Edwards Lifesciences Corp (EW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Edwards Lifesciences (EW) CEO sells 523 shares under Rule 10b5-1 plan - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Lifesciences Corp (EW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Edwards Lifesciences (EW) Hits 52-Week High on Medicare Coverage Proposal - GuruFocus
Edwards Lifesciences (EW) Sees Gains Following CMS Coverage Prop - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences (EW) Sees 3% Rise Following CMS Coverage An - GuruFocus
Edwards Lifesciences (EW) Sees Positive Coverage Update Boosting Stock Prospects - GuruFocus
Edwards Lifesciences (EW) Gains Analyst Support Amid Coverage Up - GuruFocus
Edwards Lifesciences (EW) Set to Gain from Medicare Coverage Exp - GuruFocus
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device - Benzinga
Edwards Lifesciences jumps as CMS posts proposed TAVR coverage update - Quiver Quantitative
Is Edwards Lifesciences Ready For Its Next Growth Phase? - Kalkine Media
Edwards Lifesciences stock hits 52-week high at $89.50 By Investing.com - Investing.com Nigeria
Edwards Lifesciences stock hits 52-week high at $89.50 - Investing.com
Why is Edwards Lifesciences stock climbing today? - Investing.com
Edwards Lifesciences stock jumps on TAVR coverage proposal - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy - Investing.com
Leerink reiterates Edwards Lifesciences stock rating on TAVR policy By Investing.com - Investing.com UK
Edwards Lifesciences Corp. stock rises Monday, still underperforms market - MarketWatch
Edwards Lifesciences Stock (US28176E1082): Valuation Metrics Under the Microscope - AD HOC NEWS
Is Edwards Lifesciences stock underperforming the Nasdaq? - MSN
Sector Gamma AS Acquires 23,422 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Parnassus Investments LLC Acquires 111,843 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Watched As Procedure Recovery Matters - Kalkine Media
Deutsche Bank AG Has $475.59 Million Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
CIBC Asset Management Inc Grows Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE:EW) Hits New 1-Year HighTime to Buy? - MarketBeat
Edwards Tricuspid Valve Gets FDA OK - Orange County Business Journal
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
Edwards Lifesciences Corp. Hits New 52-Week High at $89.14 - MarketsMojo
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Edwards Holds Annual Patient Experience Day - Orange County Business Journal
Is Edwards Lifesciences Stock Underperforming the Nasdaq? - Barchart.com
TD Cowen Maintains Edwards Lifesciences(EW.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bank of New York Mellon Corp Sells 1,517,638 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
TD Cowen raises Edwards Lifesciences stock price target on TAVR market share gains - Investing.com
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.86%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):